Certara, Inc. (NASDAQ:CERT) Stock Has Average Target Price of $9.18 According to Analysts

Key Points

• Analysts maintain a “Hold” consensus on Certara, with six hold, four buy, one strong-buy and one sell rating among 12 analysts. The average 12-month price target is $9.18, below the stock’s reported opening price of $9.45.
• Certara’s latest quarterly results fell short of expectations: adjusted EPS was $0.08 versus a $0.09 consensus, while revenue of $93.27 million missed estimates of $98.09 million and declined 10.8% year over year.
• Institutional ownership stands at 73.96%, with major investors including BlackRock, Haveli Investment Management and Bank of New York Mellon establishing or adding positions during the reported periods.

Shares of Certara, Inc. (NASDAQ:CERT - Get Free Report) have been assigned an average rating of "Hold" from the twelve analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $9.18.

CERT has been the subject of several research reports. Weiss Ratings lowered Certara from a "sell (d)" rating to a "sell (d-)" rating in a report on Thursday, October 8th. KeyCorp raised their target price on Certara from $9.00 to $12.00 and gave the stock an "overweight" rating in a research report on Friday. Barclays boosted their target price on Certara from $7.50 to $9.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 7th. UBS Group reaffirmed a "neutral" rating and set a $10.00 price target on shares of Certara in a research report on Wednesday, September 30th. Finally, TD Cowen increased their price target on Certara from $9.00 to $11.00 and gave the stock a "buy" rating in a research note on Tuesday, October 13th.

Certara Stock Up 0.9%

CERT opened at $9.45 on Tuesday. Certara has a twelve month low of $4.45 and a twelve month high of $12.94. The company's 50-day moving average price is $8.57 and its two-hundred day moving average price is $7.01. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -21.00 and a beta of 1.42. The company has a quick ratio of 2.55, a current ratio of 2.55 and a debt-to-equity ratio of 0.30.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $93.27 million for the quarter, compared to analysts' expectations of $98.09 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%. The company's revenue for the quarter was down 10.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.07 EPS. As a group, equities analysts expect that Certara will post 0.22 earnings per share for the current year.

Institutional Investors Weigh In On Certara

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CERT. Deutsche Bank AG bought a new stake in Certara during the 2nd quarter valued at $803,000. Granite Investment Partners LLC purchased a new stake in shares of Certara during the first quarter worth $2,130,000. Haveli Investment Management LLC purchased a new stake in shares of Certara during the second quarter worth $48,470,000. Bank of New York Mellon Corp purchased a new stake in shares of Certara during the second quarter worth $4,788,000. Finally, BlackRock Inc. bought a new position in shares of Certara in the second quarter worth $123,259,000. 73.96% of the stock is currently owned by institutional investors.

Certara Company Profile

Certara, Inc NASDAQ: CERT provides software and technology-enabled services for the biopharmaceutical industry. The company helps drug developers use regulatory science, data analysis, and modeling and simulation to support decisions throughout the research, development, and commercialization lifecycle.

Its offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial design, patient and disease modeling, regulatory submissions, and real-world data analysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.